BI 3720931 is a first-in-class, inhaled lentiviral vector-based gene therapy that could potentially address unmet needs by inserting a functional copy of the CFTR gene in the DNA of airway epithelial ...

Lentiviral vectors (LVVs ... has its own peculiarities and associated complexity when compared with other vector types, especially because of the intrinsic characteristics of the vectors ...

Boehringer Ingelheim, the UK Respiratory Gene Therapy Consortium (GTC), IP Group and Oxford BioMedica (OXB) have commenced ...

OXB announces that its proprietary lentiviral vector manufacturing technology will be used in Boehringer Ingelheim’s newly initiated LENTICLAIR ...

Lentiviral Vectors Market Size 2025 Lentiviral Vectors Market is estimated to be valued at US$ 292 million in 2023 and is expected to exhib ...

A live webcast of the fireside chat will be available on the 'Investor Relations' section of OXB's website under 'Results, ...

Ligand Pharmaceuticals (Nasdaq: LGND) has entered into a royalty financing agreement with Castle Creek Biosciences, providing ...

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their ...

Capital will fund Castle Creek’s D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through ...